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Background: Prescription and use of antidepressants and benzodiazepines are common in the general population.
Prescription of psychotropic drugs is a complex process: patient, physician and healthcare characteristics mediate,
interact and influence it. The current study aimed to establish the prevalence and factors associated with the use of
antidepressants (ADs) and benzodiazepines (BZDs) in Singapore.
Methods: The Singapore Mental Health Study (SMHS) was a nationally representative survey of Singapore Residents
aged 18 years and above. Face-to-face interviews were conducted from December 2009 to December 2010. The
diagnoses of mental disorders were established using the Composite International Diagnostic Interview version 3.0
(CIDI-3.0). The pharmacoepidemiology section was used to collect information on medication use.
Results: The overall prevalence estimates for ADs and BZDs use during the 12 months prior to the interview were
1.1% and 1.2% respectively. In all, 2.0% had used ADs and/or BZDs. ‘Help seeking for emotional or mental health
problems’ was the most important predictor for the use of ADs and BZDs—help seekers were much more likely to
use ADs (adjusted OR: 31.62, 95% CI: 13.36–74.83) and more likely to use BZDs than non-help seekers in the
previous 12 months (adjusted OR: 34.38, 95% CI: 12.97–91.16). Only 27.6% of those with 12-month major depressive
disorder (MDD) had sought formal medical help for their problems and ADs were being used by just over a quarter
of this ‘help-seeking group’ (26.3%).
Conclusions: We found that the use of ADs and BZDs in our population was relatively low, and ‘help-seeking’ was
the most important predictor of the use of ADs and BZDs. In concordance with research from other Western
countries, use of ADs was low among those with 12-month MDD.
Keywords: Antidepressant, Benzodiazepine, Major depressive disorder, Alcohol use disorder, SurveyBackground
Population based surveys from Europe and North America
have suggested that prescription rates of psychotropic
drugs range from 10 to 15% in the population [1-3], with
the most common being the prescription and use of anti-
depressants (ADs) and benzodiazepines (BZDs). A study
of six countries across Europe found that 4.38% and 9.17%
of the total sample reported the use of ADs and BZDs in
the past 12-months [4].* Correspondence: Mythily@imh.com.sg
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distribution, and reproduction in any mediumPrescription of psychotropic drugs is a complex process:
patient, physician and healthcare characteristics mediate,
interact and influence it. It has been consistently reported
that the consumption of psychotropic medications in-
creases with age [5-8], is higher among women [5,7,9],
among those with lower education [4,5,8] and the un-
employed [10,11]. Mojtabai [12] showed that patients
seeking help for depression and anxiety disorders from
psychiatrists received ADs more frequently than if they
were seeing primary care physicians. The nature and
setting of the healthcare service such as primary versus
tertiary healthcare setting, public versus private insti-
tutions, medical insurance systems, also influenceentral Ltd. This is an Open Access article distributed under the terms of the
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further influence the prescription and use of these
medications for example, Bellantuono et al. [13] found the
perception of a social problem by a General Practitioner
(GP) doubled the probability of a psychotropic drug being
prescribed in women but not men; Taggart et al. [14]
found that male physicians prescribed psychotropic drugs
at a significantly higher rate for female patients as com-
pared to female physicians.
The growing phenomenon of the pervasive use of ADs
has given rise to questions regarding the appropriateness
of their prescription as well as the rising costs. On the
other hand, epidemiological surveys have uncovered
large treatment gaps among those with major depressive
disorder (MDD). Results from the European Study of the
Epidemiology of Mental Disorders (ESEMeD) [15] showed
that 63.5% of those with 12-month diagnosis of any mood
disorder did not consult any formal health services, and
among those who sought help, only 71% were prescribed a
medication. The Singapore Mental Health Study (SMHS)
showed that the treatment gap for those with lifetime
MDD was 59.6% while that of dysthymia was 46.8% [16].
However, little is known in Singapore about the prevalence
of AD use in the community. Previous studies on the pre-
scription of psychotropic medications in Singapore were
largely limited to populations undergoing psychiatric
treatment in specialized clinical settings [17,18].
Singapore is a city-state in South-East Asia with a multi-
ethnic population that totals 5 million. A principal feature
of Singapore’s healthcare philosophy is the emphasis on
individual responsibility and the need for co-payment for
services provided. It has a dual healthcare system with a
public and private sector where affordability of healthcare
is ensured with the 3 Ms: Medisave, a national mandatory
healthcare saving plan; Medishield, a national low cost
medical insurance; and Medifund, where subsidies are
provided for the needy through a national fund. Patients
seeking treatment in public hospitals may apply for a
range of subsidies on their total bill; the extent of subsidy
received is subjected to guidelines set by the government
to allocate limited resources to those who need them
most. Mental health services are provided mainly by
psychiatrists and primary care doctors. GPs provide 80%
of the primary healthcare services, and doctors in govern-
ment polyclinics provide the remaining 20%. Public hospi-
tals (referred to as restructured hospitals) provide about
80% of the tertiary care in Singapore, while the remaining
are provided by private hospitals.
The main objectives of this study were to establish
the prevalence of AD and BZD use and their associated
factors in Singapore. We examined the effect of socio-
demographic factors, diagnosis of mood, anxiety or al-
cohol use disorders, disability due to mental disorders,
help-seeking as well as the presence of comorbidchronic physical condition on the use of ADs and
BZDs across a national sample in Singapore.
Methods
Sample
The Singapore Mental Health Study (SMHS) was a na-
tionally representative survey of Singapore Residents
aged 18 years and above. A disproportionate stratified
sampling was used where the 3 main ethnic groups
(Chinese, Malays, and Indians) were sampled in equiva-
lent proportion of about 30% each and the remaining 10%
belonged to ‘Other’ ethnic groups. This was to address the
possibility of not getting an adequate sample in minority
ethnic groups to accurately establish the prevalence of an
uncommon disorder. The sample size was derived from a
statistical power calculation for binary proportions using
previously established prevalence rates of mental disorders
in Singapore. We found the margin of error using this
sample distribution for the overall prevalence estimate
was between 1.5%—3.0%, while the margin of error for the
strata defined by age and ethnic groups was 1.0—3.5%. As
the margin of error (or precision) of a binary proportion
depends on the estimate, we also computed the relative
standard error (RSE), which was below 30%.
The respondents were randomly selected from a National
registry and approached at the household address provided
by the registry. The study was approved by the relevant
institutional ethics committee (National Healthcare Group
Domain Specific Review Board) and written informed con-
sent was obtained from all respondents. Face-to-face inter-
views were conducted by trained lay interviewers, and the
household survey was conducted from December 2009 to
December 2010. 6,616 respondents completed the inter-
view, giving a survey response rate of 75.9%. The study
methodology is described in detail in an earlier article [19].
Assessments
The diagnoses of mental disorders were established using
the Composite International Diagnostic Interview version
3.0 (CIDI-3.0) [20]. We used the Computer Assisted
Personal Interviewing (CAPI) version of the CIDI 3.0 in
English and Chinese, and the paper and pencil interview
(PAPI) version of the Malay CIDI. Diagnostic modules for
lifetime and 12-month prevalence of mood disorders
(MDD and Dysthymia), anxiety disorders (generalized
anxiety disorder (GAD), and obsessive compulsive dis-
order (OCD)) and alcohol use disorders (alcohol abuse
and alcohol dependence) were included in the survey.
Diagnostic hierarchy rules and organic exclusion criteria
were applied to all diagnoses. Help-seeking was assessed
by analyzing the services module; help-seekers for the
purposes of this study were defined as those who had
consulted with any formal healthcare provider (i.e. psych-
iatrist, GP or any other medical doctor as only these
Table 1 Socio-demographic characteristics of the study
sample (N = 6616)
Unweighted Weighted Population figures by
Singapore census,
2010
n % % (SE) %
Age
Mean (SE), SD 42.0 14.5 43.9(0.3)
Age Group
18-34 2293 34.7 31.7(0.0) 31.2
35-49 2369 35.8 34.1(0.0) 32.2
50-64 1542 23.3 23.1(0.0) 25.1
65+ 412 6.2 11.1(0.0) 11.4
Ethnicity
Chinese 2006 30.3 76.9(0.0) 74.1
Malay 2373 35.9 12.3(0.0) 13.4
Indian 1969 29.8 8.3(0.0) 9.2
Others 268 4.1 2.4(0.0) 3.3
Gender
Female 3317 50.1 51.5(0.9) 49.3
Male 3299 49.9 48.5(0.9) 50.7
Marital Status
Never Married 1825 27.6 28.9(0.6)














Vocational 721 10.9 7.9(0.4)
University 1342 20.3 21.9(0.7)
Employment
















*Economically Inactive refers to retirees, housewives and students.
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chotropic drugs). The pharmacoepidemiology module of
CIDI-3.0 was used to establish the use of ADs and BZDs
in the population. The key questions, “Did you take any
type of prescription medicine in the past 12 months for
problems with your emotions, substance use, energy, con-
centration, sleep, or ability to cope with stress? Include
medicines even if you took them only once” was asked to
all respondents regardless of diagnostic status. A respond-
ent booklet with names of various psychotropic medica-
tions was used to aid recall. Interviewers were also trained
to encourage respondents to refer to prescriptions/
medications to aid recall and provide precise answers.
The raw data was reviewed, cleaned and medications
were classified into different groups by a research as-
sistant working closely with the principal investigator
and co-author (SAC), who is an experienced research
psychiatrist in Singapore.
We used a modified version of the CIDI 3.0 checklist
of chronic medical conditions to capture information
on chronic physical disorders which were considered
prevalent in Singapore’s population. Socio-demographic
information was collected using a structured questionnaire.
Disability was assessed with the Sheehan Disability Scale
(SDS) which examined functioning in work, household,
relationship, and social roles in the worst month of the
past year. The Quick Inventory of Depressive Symptom-
atology Self-Report (QIDS-SR) [21], included in the CIDI
3.0 assessed symptom severity in MDD during the worst
month of the previous year. Transformation rules devel-
oped for the QIDS-SR were used to convert the scores
into clinical severity scores and categories of the Hamilton
Rating Scale of Depression (HAMD) [22,23].
Statistical analyses
All estimates were weighted to adjust for over sampling
and post-stratified for age and ethnicity distributions
between the survey sample and the Singapore resident
population in 2007. Estimates of the prevalence of ADs
and/or BZDs usage were expressed in weighted percent-
ages with standard error (SE/100). Chi square (χ2) tests
were used to compare the prevalence rates between the
groups. A series of multiple logistic regression models
were used to generate odds ratios (ORs) and 95% confi-
dence intervals using consumption of ADs, BZDs and
ADs and/or BZDs as the main outcome variables and
age group, ethnicity, gender, marital status, education,
employment, help seeking, presence of chronic physical
disorder, alcohol use disorder, anxiety disorders, bipolar
disorder, dysthymia and MDD as the predictor variables.
Statistical significance was evaluated at the p < 0.05 level
using two-sided tests. All statistical analyses were carried
out using the Statistical Analysis Software (SAS) System
version 9.2 (Cary, NC).
Table 2 12-month prevalence of antidepressants and benzodiazepines in the population by sociodemographic and
clinical factors
AD BZD AD and/or BZD#
(n = 57) (n = 60) (n = 104))
Variables N % (SE) X2 (DF) P value N % (SE) X2 (DF) P value N % (SE) X2 (DF) P value
All respondents 1.09 0.2 1.15 0.2 1.95 0.26
Age Group
18-34 17 0.48 0.17 5.7(3) 0.13 26 1.02 0.28 1.8(3) 0.62 40 1.46 0.32 1.6(3) 0.66
35-49 20 1.07 0.32 21 1.51 0.39 37 2.22 0.46
50-64 17 1.6 0.48 11 0.77 0.32 23 1.99 0.53
65+ 3 1.8 1.03 2 1.2 0.85 4 2.41 1.19
Ethnicity
Chinese 22 1.18 0.26 7.9(3) 0.054 24 1.23 0.25 17.5(3) 0.0006 40 2.07 0.33 23.5(3) <.0001
Malay 11 0.45 0.14 12 0.5 0.14 19 0.79 0.18
Indian 19 0.94 0.22 16 0.81 0.2 33 1.64 0.28
Others 5 1.84 0.86 8 3.24 1.17 12 4.86 1.41
Gender
Male 23 0.97 0.27 0.3(1) 0.56 27 1.15 0.3 0(1) 1 44 1.73 0.36 0.7(1) 0.42
Female 34 1.2 0.3 33 1.15 0.26 60 2.15 0.38
Marital Status
Single 15 1.18 0.36 3.6(2) 0.16 18 1 0.31 0.4(2) 0.83 31 2.14 0.47 3.1(2) 0.21
Married 34 0.88 0.23 38 1.24 0.27 61 1.67 0.31
Divorced/Separated/
Widowed
8 2.28 1.08 4 1.01 0.6 12 3.29 1.23
Education
Pre-Primary/Primary 15 1.92 0.65 11.3(4) 0.02 5 0.44 0.27 4.5(4) 0.34 17 2.12 0.67 2.4(4) 0.66
Secondary 15 1.44 0.45 17 1.43 0.47 28 2.34 0.57
Pre-U/JC/Diploma 12 0.57 0.25 16 1.33 0.42 26 1.7 0.46
Vocational 4 0.25 0.13 6 0.74 0.45 9 0.93 0.46
University 11 0.71 0.3 16 1.42 0.45 24 1.9 0.51
Employment Status
Employed 30 0.73 0.18 8.3(2) 0.02 41 0.99 0.21 1.4(2) 0.50 64 1.57 0.26 4.9(2) 0.09
Econ. Inactive* 18 1.82 0.59 13 1.52 0.53 26 2.71 0.7
Unemployed 5 2.73 1.45 2 1.71 1.19 6 3.59 1.67
Help Seeking
No 21 0.41 0.13 192.9(1) <.0001 19 0.36 0.12 266.6(1) <.0001 39 0.76 0.18 346.4(1) <.0001
Yes 36 12.94 2.7 41 14.88 2.82 65 22.57 3.27
Chronic physical disorder
No 20 0.8 0.23 2.7(1) 0.1 21 0.74 0.2 6.0(1) 0.01 36 1.32 0.28 7.8(1) 0.005
Yes 37 1.47 0.36 39 1.71 0.38 68 2.79 0.48
Mental disorders
Alcohol use disorder
Never 50 1.06 0.2 1.2(2) 0.55 49 1 0.19 17.7(2) 0.0001 88 1.77 0.26 15.4(2) 0.0004
Lifetime, 5 1.93 1.33 8 4.56 2.13 11 6.15 2.47
12-month 2 1.33 0.96 3 6.92 4.98 5 8.26 5.05
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Table 2 12-month prevalence of antidepressants and benzodiazepines in the population by sociodemographic and
clinical factors (Continued)
Anxiety disorder
Never 46 0.97 0.2 26.5(2) <.0001 47 0.98 0.19 24.3(2) <.0001 85 1.71 0.25 32.3(2) <.0001
Lifetime, 9 6.22 2.84 7 6.4 2.96 12 10.2 3.63
12-month 2 1.11 0.85 6 4.6 2.73 7 5.38 2.83
Bipolar disorder
Never 55 1.09 0.2 - - 54 1.1 0.2 8.3(2) 0.02 96 1.9 0.26 4.3(2) 0.12
Lifetime, 0 - - 1 6.18 5.95 1 6.18 5.95
12-month 2 1.32 0.97 5 4 1.9 7 5.32 2.19
Dysthymia
Never 55 1.05 0.2 16.8(1) <.0001 57 1.13 0.2 9.4(1) 0.002 100 1.89 0.26 19.8(1) <.0001
12-month 2 15.68 12.51 3 7.45 4.94 4 21.27 12.84
Major depressive disorder
Never 38 0.8 0.18 49.6(2) <.0001 42 0.85 0.18 46.6(2) <.0001 74 1.48 0.24 67.1(2) <.0001
Lifetime, 6 3.52 1.8 6 4.47 1.99 11 6.92 2.43
12-month 13 9.17 3.3 12 8.54 3.21 19 13.47 3.88
Any mental disorders
Never 27 0.73 0.19 29.9(2) <.0001 27 0.67 0.17 50.6(2) <.0001 51 1.24 0.24 64.5(2) <.0001
Lifetime, 14 2.94 1.08 13 3.89 1.26 23 6.13 1.56
12-month 16 4.96 1.73 20 6.1 1.89 30 8.9 2.23
#Those who were prescribed either Antidepressants OR Benzodiazepine or were prescribed both Antidepressants AND Benzodiazepine.
Lifetime prevalence does not include 12-month prevalence.
*Economically Inactive refers to retirees, housewives and students.
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The mean age of respondents was 43.9 years and the
sample consisted of almost equal proportions of males
and females. Table 1 shows the sociodemographic distri-
bution of the respondents.
Antidepressants/benzodiazepines use
The overall prevalence estimates for ADs and BZDs use
during the 12 months prior to the interview were 1.1%
and 1.2% respectively. In all, 2.0% had used ADs and/or
BZDs. More than one-quarter of the people using ADs
(26.7%) also used BZDs. The prevalence rates of ADs
and BZDs use were significantly different across ethni-
city, education and employment status. ‘Help-seeking for
emotional problems’ was strongly associated with the
use of ADs and BZDs. The unadjusted prevalence esti-
mates revealed that a diagnosis of any mental disorder
(alcohol use disorder, anxiety disorder, bipolar disorder,
dysthymia or MDD was associated with more prevalent
use of ADs and BZDs (Table 2).
Help-seeking significantly increased the use of ADs and
BZDs in subjects with a lifetime or 12-month diagnosis of
any mental disorder. For help-seekers with alcohol use
disorder, the use of BZDs was much higher than the use
of ADs. About one third (33.2%) of the help-seekers with
lifetime alcohol use disorder used BZDs and about half(45.3%) of those with 12-month alcohol use disorder used
BZDs. For help-seekers with anxiety disorder, the use of
ADs was comparable to the use of BZDs in respondents
with lifetime prevalence whereas the use of BZDs was
much higher than the use of ADs among those with 12-
month anxiety disorder. For help-seekers with bipolar
disorder the use of BZD was much higher than the use
of ADs among respondents with both life-time and 12-
month disorder. For help-seekers with MDD, the use of
ADs was comparable to the use of BZDs in respondents
with both lifetime and 12-month disorder (Table 3).
There were significant differences in the use of ADs
(χ2 = 36.7, p value < 0.0001) based on the type of profes-
sionals that the respondents had consulted for their ‘emo-
tional or mental health problems’ in the 12 months
preceding the interview (Table 4). Chi-square test revealed
that the ratings of the Hamilton Depression Rating Scale
(HAM-D) and Sheehan disability scale (SDS) were not
associated with the use of any of the medications.
Multivariate analysis
Table 5 shows the results of the multivariate logistic ana-
lysis. ‘Help-seeking for emotional or mental health prob-
lems’ was the most important predictor for the use of ADs
and BZDs —help-seekers were much more likely to use
ADs and BZDs than non-help-seekers in the previous 12
Table 3 Individuals being prescribed antidepressants or
benzodiazepines during the last 12 months by diagnostic





Mental disorder Prevalence AD BZD AD BZD
% % % %
Alcohol use disorder Never 0.42 0.33 12.71 13.22
Lifetime 0.16 1.49 18.47 33.18
12-month 0.00 0.61 9.43 45.30
Anxiety disorder Never 0.37 0.32 12.80 13.95
Lifetime 2.12 2.08 24.98 26.17
12-month 0.45 0.83 2.84 14.62
Bipolar disorder Never 0.41 0.36 14.03 15.16
Lifetime 0.00 0.00 0.00 12.00
12-month 0.00 1.03 4.93 12.13
Dysthymia Never 0.37 0.36 13.18 14.96
12-month -(*) 2.95 3.71 11.93
Major depressive disorder Never 0.33 0.29 11.34 13.36
Lifetime 1.50 2.56 10.57 11.15
12-month 2.65 0.55 26.34 29.55
No Disorder 0.30 0.26 12.69 11.98
Antidepressants — %/12 months (SE ranging from 0.13 to 12.3).
Benzodiazepines — %/12 months (SE ranging from 0.12 to 25.0).
Lifetime prevalence does not include 12-month prevalence.
*not reported due to the small number of people with dysthymia not
seeking help.
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Malays’ usage of BZDs was significantly lower than that of
the Chinese. Those who were married were less likely to
use ADs compared to those who were single. Respondents
who had pre-primary or primary education were 3.5 times
more likely to use ADs than respondents with university
education. Age group, gender and employment status
were not associated with the use of either ADs or BZDs.
Respondents with a diagnosis of lifetime alcohol use dis-
order or lifetime anxiety disorder were more likely to use
BZDs than those without these disorders. A diagnosis of
12-month MDD was associated with the use of ADs and
BZDs. The multivariate analysis revealed that the presence
of a bipolar disorder, dysthymia or chronic physical disor-
ders did not have a predictive utility for the use of either
ADs or BZDs.Table 4 Percentage of subjects taking antidepressants or ben
General practitioner, Other medical doctor)
Psychiatrist Ge
N % N
Antidepressant (%) 32 21.39 5
Benzodiazepine (%) 27 17.13 18
Antidepressants or Benzodiazepines (%) 50 30.06 21Discussion
The overall prevalence estimates for ADs and BZDs use
during the 12 months prior to the interview were 1.1%
and 1.2% respectively, with 2.0% using ADs and/or
BZDs. These rates were lower than those found in the
ESEMeD project where 4.38% of the respondents had
taken ADs and 9.17% had used BZD in the past 12
months, while overall, 11.68% of their sample had used
ADs or BZD [4]. Our rates were slightly lower than
that of 2.0% AD use reported from the Israel National
Health survey [8]. We would like to highlight that the
rates of MDD as established in the SMHS (lifetime and
12-month prevalence estimates for MDD were 5.8%
and 2.2%, respectively) [24,25] were lower than those
reported by the ESEMeD project (lifetime and 12-month
prevalence estimates for MDD were 12.8% and 3.9%,
respectively) [26].
Sociodemographic factors that were associated with
the use of ADs and BZDs included ethnicity, marital
status, and education. Indicators of social exclusion such
as not being married and low education have been associ-
ated with low social support and increased psychological
distress and this may be correlated to higher utilization of
ADs in these groups [27,28]. We did not find age or
gender to be correlated with the use of ADs and BZDs.
Those seeking help from psychiatrists were significantly
more likely to use ADs as compared to those seeking help
from GPs or other medical doctors, while the use of BZDs
was not significantly associated with their source of help-
seeking. The US National Comorbidity Survey similarly
found that individuals with a mood or anxiety disorder
were more likely to receive ADs and anxiolytics from psy-
chiatrists than from primary care physicians [12]. A recent
questionnaire based study among psychiatrists and GPs in
Belgium found that more psychiatrists than GPs are high
prescribers of ADs (prescribed antidepressants to > 50% of
their patients with depression) [29]. The authors suggested
that this could be due to differences in the severity of
depression among those seeking help from psychiatrists
and GPs. However, our study did not find any association
with either functional or symptom severity and use of
ADs.
As with other studies [4,15], we found that a large pro-
portion of those with 12-month MDD were not pre-
scribed ADs. This could be due to a failure to recognizezodiazepines, within each source of help (Psychiatrist,
neral practitioner Other medical doctor
% N % P value
2.37 2 4.15 <.0001
15.99 2 4.24 0.14
17.95 3 6.32 0.003
Table 5 Logistic regression analysis on sociodemographic and clinical factors associated with the prescription of
antidepressants/benzodiazepines/both
AD BZD AD and/or BZD
Variable OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age Group
18-34 Ref. Ref. Ref.
35-49 2.91 (0.75,11.35) 0.12 1.27 (0.42,3.85) 0.67 1.91 (0.75,4.82) 0.17
50-64 3.49 (0.82,14.76) 0.09 0.6 (0.14,2.59) 0.49 1.35 (0.44,4.09) 0.60
65+ 4.67 (0.54,40.56) 0.16 1.4 (0.19,10.53) 0.75 2.2 (0.44,10.93) 0.34
Ethnicity
Chinese Ref. Ref. Ref.
Malay 0.39 (0.15,1.01) 0.05 0.38 (0.16,0.88) 0.02 0.33 (0.16,0.67) 0.002
Indian 0.96 (0.46,2) 0.91 0.5 (0.23,1.06) 0.07 0.72 (0.41,1.28) 0.26
Others 1.15 (0.27,4.91) 0.85 0.81 (0.24,2.7) 0.73 1.14 (0.42,3.1) 0.79
Gender
Male Ref. Ref. Ref.
Female 1.27 (0.48,3.36) 0.64 0.96 (0.42,2.18) 0.912 1.31 (0.66,2.62) 0.45
Marital Status
Single Ref. Ref. Ref.
Married 0.29 (0.1,0.85) 0.02 1.13 (0.39,3.29) 0.83 0.43 (0.19,1) 0.05
Divorced/Separated/Widowed 0.42 (0.06,2.73) 0.36 0.69 (0.08,5.88) 0.73 0.58 (0.14,2.44) 0.46
Education
Pre-Pri/Primary 3.53 (1.06,11.75) 0.04 0.52 (0.08,3.29) 0.48 1.73 (0.62,4.78) 0.29
Secondary 1.96 (0.57,6.68) 0.28 1.23 (0.41,3.67) 0.71 1.42 (0.59,3.43) 0.44
Pre-U/JC/Diploma 0.7 (0.16,3.03) 0.64 1.1 (0.37,3.28) 0.86 0.88 (0.35,2.22) 0.79
Vocational 0.29 (0.05,1.73) 0.17 0.57 (0.17,1.97) 0.38 0.43 (0.14,1.32) 0.14
University Ref. Ref. Ref.
Employment Status
Employed Ref. Ref. Ref.
Econ. Inactive* 1.53 (0.67,3.53) 0.32 1.28 (0.57,2.89) 0.55 1.22 (0.63,2.36) 0.56
Unemployed 0.66 (0.13,3.31) 0.61 0.76 (0.15,3.76) 0.73 0.67 (0.22,2.03) 0.47
Help Seeking
No Ref. Ref. Ref.
Yes 31.62 (13.36,74.83) <.0001 34.38 (12.97,91.16) <.0001 32.18 (15.87,65.26) <.0001
Chronic Physical Disorder
No Ref. Ref. Ref.
Yes 0.92 (0.36,2.39) 0.87 1.63 (0.69,3.85) 0.27 1.31 (0.65,2.65) 0.46
Mental disorders
Alcohol use disorder
Never Ref. Ref. Ref.
Lifetime 2.02 (0.6,6.72) 0.25 5.18 (1.77,15.16) 0.003 4.28 (1.7,10.78) 0.002
12-month 0.78 (0.07,8.89) 0.84 3.41 (0.55,21.06) 0.19 2.82 (0.57,14.04) 0.21
Anxiety disorder
Never Ref. Ref. Ref.
Lifetime 4.05 (0.96,17.12) 0.06 3.48 (1.03,11.76) 0.04 4.49 (1.47,13.67) 0.008
12-month 0.13 (0.01,1.32) 0.08 0.88 (0.17,4.47) 0.87 0.62 (0.14,2.78) 0.53
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Table 5 Logistic regression analysis on sociodemographic and clinical factors associated with the prescription of
antidepressants/benzodiazepines/both (Continued)
Bipolar disorder
Never Ref. Ref. Ref.
Lifetime - - 0.52 (0.08,3.47) 0.50 0.27 (0.04,1.86) 0.18
12-month - - 2.04 (0.45,9.28) 0.36 1.77 (0.51,6.17) 0.37
Dysthymia
Never Ref. Ref. Ref.
12-month 0.98 (0.02,43.52) 0.99 0.45 (0.05,4.24) 0.48 0.91 (0.05,16.04) 0.95
Major depressive disorder
Never Ref. Ref. Ref.
Lifetime 1.3 (0.23,7.17) 0.77 1.59 (0.36,7.08) 0.54 1.42 (0.4,5.05) 0.59
12-month 7.6 (2.28,25.39) 0.001 4.45 (1.5,13.19) 0.007 4.12 (1.63,10.45) 0.002
*Economically Inactive refers to retirees, housewives and students.
Lifetime prevalence does not include 12-month prevalence.
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available treatments or due to the considerable stigma
associated with mental illnesses. Therefore, until people
conceive that they require some help, they may not seek
treatment. Even in those seeking help, various factors
associated with the care-providers may further limit the
prescription of ADs [30].
The adjusted analyses showed that the strongest pre-
dictor for the use of ADs and BZDs was “help-seeking”
behavior. It is possible that those who are help-seeking
had a sub-clinical presentation which while not meeting
any DSM-IV diagnosis criteria, caused the respondents
significant distress and functional impairment leading to
the prescription. It is also possible that the medications
were prescribed for other disorders that were not in-
cluded in our study. Lastly, the question on help-seeking
specifies, “seeking help for problems with your emotions,
nerves, mental health or your use of alcohol or drugs”;
thus it is possible that some respondents with a mental
disorder failed to perceive their problems as such and
sought help for other complaints such as somatic symp-
toms, and therefore ascribed a more physical cause to
their illness. The use of ADs was more prevalent among
respondents with 12-month prevalence of MDD than in
respondents with lifetime prevalence of MDD. The
Singapore Clinical Practice Guidelines for Depression
[31] recommends that patients with a first episode of
depression without psychotic symptoms should be
treated with ADs at full treatment dose for 6–9 months
after remission of symptoms and that patients who have
a second episode of depression should be maintained
on treatment for 1–2 years, this provides a possible
explanation as to why only about 13% of those with
lifetime MDD were using ADs. Lifetime or 12-month
bipolar disorder was not associated with the use of ADs
or BZDs. In a previous report, we found that theproportion of respondents prescribed treatment with
antipsychotic, AD and/or mood-stabilizer among those
with 12-month bipolar disorder were 1.6%, 1.3% and 7.1%
respectively [32], reflecting a preference of prescribing
mood stabilizer as the mainstay of psychopharmacotherapy
for bipolar disorder Help-seeking respondents with both
12-month MDD and anxiety disorders were more likely to
use BZDs than ADs. Studies have suggested that patients
often consult physicians for somatic or sleep complaints
and only a high degree of suspicion and careful screening
would reveal the underlying mental disorder [33], thus
symptomatic treatment would result in misdiagnosis
and inadequate treatment of the primary disorder,
which could result in adverse outcomes. Other studies
have similarly found that BZDs are commonly pre-
scribed to those with mood and anxiety disorders [4,34].
Most recent international treatment guidelines [35,36]
further, recommend limiting the use of BDZs only in
patients with primary major depression to those with
pronounced anxiety or persistent insomnia that are not
adequately relieved by ADs. International guidelines for
anxiety disorders [35,37] currently recommend selective
serotonin reuptake inhibitors (SSRIs) and serotonin/
norepinephrine reuptake inhibitors (SNRIs) as the drugs
of first choice, with BZDs as second-line option.
We found the use of BZDs to be significantly higher
among those with lifetime alcohol use disorders. Alcohol
dependence and the associated use of legal psychotropic
drugs have been identified in several clinical studies
[38-40]. Those with alcohol use disorders may use BZDs
with alcohol or as a substitute when alcohol is unavail-
able. They may also self-medicate with BZDs to ease
alcohol’s withdrawal symptoms or for comorbid anxiety
disorders. A recent Treatment Episode Data Set (TEDS) re-
port from US suggested that ‘since BZD abuse is most often
a secondary substance of abuse, prescribing physicians may
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monitor patients more closely’ [41].
The limitations of our study include the fact that the
data were entirely based on self-report and the willingness
of the respondents to disclose the use of medications, thus
our rates are possibly underestimates. Studies have dem-
onstrated that there is good concordance between self-
reported psychotropic medication use and information
obtained from official prescription databases for most
psychotropic drugs [42]. Our study did not establish non-
pharmacological treatments, thus it may be possible that
those with anxiety or mood disorder were receiving behav-
ioral interventions which may have resulted in some of
our findings. As this was a household study, we excluded
those who were in institutions such as hospitals/nursing
homes and prisons during the field period of the study and
these populations may have a higher use of psychotropic
medications.
The strengths of our study are the use of a structured
standardized instrument and well trained interviewers who
captured the information systematically and accurately. We
also achieved a relatively high response rate of 75.9% which
makes the findings generalizable to the resident population.
Conclusions
In conclusion, we found that use of ADs and BZDs in our
population was relatively low and that ‘help-seeking’ was
the most important predictor of the use of ADs and BZDs.
What needs to be further investigated is the appropriate-
ness of the use of these psychotropic medications – a
question which was beyond the scope of this study. How-
ever, it would seem there might be an underutilization of
ADs among those with 12-month MDD (although we
could not establish whether these respondents have re-
ceived any form of psychotherapy), as well as a relatively
high rate of BZDs use among those with alcohol use
disorders. However, these findings need to be further
researched in this population.
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